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The R47H variant in the microglial triggering receptor expressed on myeloid cell 2
(TREM2) receptor is a strong risk factor for Alzheimer’s disease (AD). To characterize
processes affected by R47H, we performed an integrative network analysis of
genes expressed in brains of AD patients with R47H, sporadic AD without the
variant, and patients with polycystic lipomembranous osteodysplasia with sclerosing
leukoencephalopathy (PLOSL), systemic disease with early-onset dementia caused by
loss-of-function mutations in TREM2 or its adaptor TYRO protein tyrosine kinase-binding
protein (TYROBP). Although sporadic AD had few perturbed microglial and immune
genes, TREM2 R47H AD demonstrated upregulation of interferon type I response and
pro-inflammatory cytokines accompanied by induction of NKG2D stress ligands. In
contrast, PLOSL had distinct sets of highly perturbed immune and microglial genes that
included inflammatory mediators, immune signaling, cell adhesion, and phagocytosis.
TREM2 knockout (KO) in THP1, a human myeloid cell line that constitutively expresses
the TREM2- TYROBP receptor, inhibited response to the viral RNA mimetic poly(I:C)
and phagocytosis of amyloid-beta oligomers; overexpression of ectopic TREM2
restored these functions. Compared with wild-type protein, R47H TREM2 had a higher
stimulatory effect on the interferon type I response signature. Our findings point to a role
of the TREM2 receptor in the control of the interferon type I response in myeloid cells
and provide insight regarding the contribution of R47H TREM2 to AD pathology.
Keywords: microglia, neurodegeneration, aging, inflammation, interferon type I response, NKG2D ligands,
senescence
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and its R47H variant, we knocked out the gene in the THP1
cells, a human myeloid line that expresses a functional TREM2TYROBP receptor.

INTRODUCTION
A proactive role of brain immune cells, microglia, in the
pathogenesis of Alzheimer’s disease (AD) gained recognition
after the discovery of AD-associated variants in the triggering
receptor expressed on myeloid cell 2 (TREM2) gene that is only
expressed on immune cells of myeloid origin. Further support
came from a large-scale genome-wide association study that
identified multiple additional immune risk factors (odds ratio
0.9–1.15) (1). Many of these immune molecules have either
microglia-specific expression (e.g., CD33, the MS4As, INPP5D,
and SPI1) or are enriched in microglia (e.g., ABCA7, CR1, and
CLU). Of all microglial genetic AD risk factors, the TREM2
R47H variant confers the highest risk of disease development,
with a risk similar to that of APOEε4 (odds ratio 4.5–2.6)
(2, 3). Loss-of-function mutations in the TREM2 receptor
or its adaptor, TYRO protein tyrosine kinase-binding protein
(TYROBP), cause polycystic lipomembranous osteodysplasia
with sclerosing leukoencephalopathy (PLOSL; Online Mendelian
Inheritance in Man # 221770), a recessive systemic disorder that
presents with early-onset dementia (4) or familial frontotemporal
dementia (5).
TREM2 is involved in multiple aspects of myeloid cell
function and interaction with other cell types (6). In microglia,
it regulates cell chemotaxis (7), enhances phagocytosis (8, 9), and
influences microglia survival, proliferation, and differentiation
(10). The complexity of TREM2 functioning is revealed in
cell/tissue content-dependent responses to stimuli of different
natures, as well as their timing. For instance, whereas
isolated TREM2-deficient cells increased production of proinflammatory molecules in vitro (8, 11), studies of intact
tissues demonstrated that both pro- and anti-inflammatory
roles of TREM2 in brain immunity are dependent on timing
after stimulation (12), stage of pathology (13), and genetic
background (14). In addition, a soluble form of TREM2,
a product of cleavage or alternative splicing, may have a
separate function as an extracellular signaling molecule that
promotes cell survival (15, 16). TREM2 binds lipids and
lipoproteins, including the known AD risk factors ApoE
and ApoJ/CLU (17–19), and mediates myelin clearance (20).
Also, TREM2 binds amyloid beta-peptide (Aβ) activating
microglia cytokine production and degradation of an internalized
peptide (9).
By exome sequencing of families affected with late-onset AD,
we identified multiple carriers of the TREM2 R47H variant (21).
TREM2 R47H AD patients demonstrated a shortened course
of the disease, pronounced synucleinopathy, changed microglial
morphology, and decreased level of the microglial marker Iba1,
suggesting that compromised TREM2 signaling has a strong
effect on microglia function in the disease. Herein, we performed
RNA expression profiling of brain tissues from subjects with
TREM2 R47H AD, sporadic AD without the variant (sAD), and
normal age-matched controls to assess the effect of R47H variant
on brain immune gene networks. We also analyzed brain tissues
of PLOSL patients with bi-allelic loss-of-function mutations in
TREM2 or TYROBP. To further investigate the role of TREM2
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MATERIALS AND METHODS
Subjects
Familial Alzheimer’s Disease and Frontotemporal
Dementia Patients With R47H
Through the University of Washington (UW) AD Research
Center, we acquired brain autopsy material of nine TREM2
R47H carriers from four unrelated families affected with AD or
frontotemporal dementia (Supplementary Tables 1, 2). Flashfrozen brain tissues from two R47H carriers were used for
RNA-seq analyses. RNA isolated from formalin-fixed, paraffinembedded (FFPE) sections of eight R47H carriers with AD were
used for gene expression by NanoString nCounter.

Sporadic Alzheimer’s Disease and Controls
Frozen and fixed autopsy tissues from neuropathologically
confirmed AD cases and aged non-demented controls were
obtained from the UW Neuropathology Core Brain Bank
(Supplementary Tables 1, 2).

PLOSL Cases Caused by Loss-Of-Function
Mutations in TREM2-TYROBP Receptor
Brain tissues were obtained from the UW Neuropathology Core
Brain Bank and the Meiji Pharmaceutical University, Tokyo,
Japan. One PLOSL patient was homozygous for a missense
variant D134G in TREM2 (4), another patient was homozygous
for a splice site mutation, c.482 + 2T > C, in TREM2 (22),
and two were homozygous for c.141delG in TYROBP (23)
(Supplementary Tables 1, 2). FFPE sections were used for RNA
isolation and NanoString nCounter analysis.
Under protocols approved by the Institutional Review
Boards of the UW and the Meiji Pharmaceutical University,
all subjects had previously given informed consent to share
and study autopsy material. All methods for processing and
analyzing the brain autopsy tissues followed relevant guidelines
and regulations.

Cell Culture and Cytokine Stimulation
A human microglia cell line HMC3 and human myeloid cell lines
THP1, U937, and MOLM13 were obtained from the American
Type Culture Collection. Cells were cultured in Dulbecco’s
modified Eagle medium (HMC3) or RPMI medium (the others)
supplemented with 10% fetal bovine serum. Pro-inflammatory
stimulation with lipopolysaccharide (LPS; Sigma, #055:B5,
0.5 µg/ml) and interferon-gamma (IFNγ; PeproTech, #300-02,
150 U/ml) was performed for 24 h. Stimulations with interleukin
(IL)-4 (PeproTech, #200-04, 20 ng/ml) or IL-10 (PeproTech,
#200-10, 20 ng/ml) were similarly performed for 24 h.
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complexes with LyoVec transfection reagent (Invivogen, tlrlpiclv, 500 ng/ml) or with a combination of poly(I:C)/LyoVec
and IFNβ (PeproTech, #300-02, 100 Units/ml) for 24 h. When
indicated, TREM2 or GFP expression was induced by 100 ng/ml
doxycycline 16–18 h before the IFN I response stimulation.

Genome Editing of TREM2 With
CRISPR/Cas9
A THP1 derivative that stably expresses Cas9 (THP1-CAS9)
was generated using a lentiviral construct (Addgene, lentiCas9Blast, #52962) after blasticidin selection. Single guide RNAs
(sgRNAs) for targeting TREM2 were selected using the
online CRISPR design tool (crispr.mit.edu) (24). THP1CAS9 cells were nucleofected with sgRNAs using a protocol
recommended for THP1 (Lonza, Amaxa 4D Nucleofector,
Protocol #292). Cutting efficiency for each guide was measured
using GeneArt Genomic Cleavage Detection Kit (ThermoFisher,
#A24372). Based on % indel efficiency, sgRNA within exon
2 (sense: ACTGGTAGAGACCCGCATCA) was chosen
for subsequent experiments. TREM2-negative cells were
enriched by cell sorting after the immunostaining of live
cells. Colonies grown from single sorted cells were sequenced;
clones with frame-shifting indel mutations inactivating all
TREM2 alleles were tested for the absence of protein by
Western blotting.

Real-Time Quantitative PCR Analysis
Total RNA from harvested cells was isolated with RNAeasy
kit (Qiagen; #74106); complementary DNA was synthesized
with SensiFast (Bioline, BIO-65053). TaqMan Fast Advanced
Master Mix and the following TaqMan Gene Expression
Assays (ThermoFisher, #4331182) were used for qRT-PCR:
MICB: Hs00792952_m1, IFNB: Hs01077958_s1, IRF7:
Hs01014809_g1, IFIH1: Hs00223420_m1, and reference
gene TBP: Hs00427620_m1. Assays were performed on a
StepOnePlus real-time PCR machine and analyzed with StepOne
software (Applied Biosystems) using the 2[−Delta Delta
C(T)] method (27). All measurements were performed in
technical duplicates.
R

Antibodies and Immunostaining

TREM2 Cloning and Overexpression

Live cells were immunostained with fluorescent polyclonal
antibodies to TREM2 (R&D Systems #MAB17291) and analyzed
by fluorescence-activated cell sorting. For Western blotting,
50 µg of whole-cell lysates was resolved on a polyacrylamide
gel, transferred to polyvinylidene fluoride membrane, and stained
with polyclonal TREM2 antibodies (Cell Signaling Technology,
#91068) at 1:1,000 dilution.

Coding sequences of human TREM2 (NM_018965.3), common
variant (CV), and R47H variant, were synthesized and cloned
into a doxycycline-inducible lentiviral pCW57-MCS1-2A-MCS2
vector (Addgene, #71782). THP1 TREM2 knockout (KO) cells
were transduced with lentiviral particles expressing either of
wild-type TREM2, R47H TREM2, or green fluorescent protein
(GFP) proteins (Addgene; pCW57-GFP-2A-MCS, #71783). After
2 weeks of puromycin selection, resistant cells were induced
with doxycycline (100 ng/ml) and tested for TREM2 and
GFP expression by real-time quantitative PCR (qRT-PCR) and
fluorescence-activated cell sorting analyses.

Gene Expression Analyses
Whole Transcriptome RNA-seq of Brain Tissues
Total RNA was isolated from flash-frozen brain tissues,
and ribosomal RNA was depleted using the Ribo Zero
Gold Magnetic system (Epicenter/Illumina, San Diego,
CA, United States). RNA-seq libraries were prepared with
the ScriptSeq v2 kit (Epicenter) and subjected to pairedend sequencing (2 × 100 bp) on an Illumina HiSeq 2500
instrument. A mean read number of 6 × 107 was generated per
sample. The following data analysis tools were used: FastQC
0.9.6 for visualizing read QC https://www.bioinformatics.
babraham.ac.uk/projects/fastqc; Bowtie 2.2.1 https://sourceforge.
net/projects/bowtie-bio/files/bowtie2/2.2.1/and TopHat 2.0.11
https://ccb.jhu.edu/software/tophat/index.shtml
for
read
alignment and splice site discovery; Cufflinks 2.1.1 http://coletrapnell-lab.github.io/cufflinks/releases/v2.1.1/for
transcript
assembly and quantification; MISO 0.5.2 https://sbgrid.org/
software/titles/miso for quantitating isoform expression levels;
and cummeRbund 2.0.0 http://compbio.mit.edu/cummeRbund
and IGV 2.3.14 http://software.broadinstitute.org/software/igv/
download for data visualization.

Phagocytosis Assay
In vitro aggregation of an Aβ (Aβ1−42 , Bachem #H-1368, 100 µM
in phosphate-buffered saline) was carried out by incubation
for 4 days at 37◦ C. The insoluble pellet was precipitated and
labeled by pHrodo Red according to the manufacturer’s protocol
(Life Technologies, #P36600). THP1 monocytes were plated
at 5 × 105 /ml density; TREM2 expression was induced by
100 ng/ml doxycycline overnight. Cells were incubated with
0.25 µg/ml Aβ-pHrodo for 3 h at 37◦ C and collected and washed
in ice-cold phosphate-buffered saline with 1% bovine serum
albumin. Uptake of Aβ-pHrodo was measured on the LSRII
Flow cytometer (BD Biosciences) and data analyzed by FlowJo.
Phagocytosis was measured as the mean fluorescence intensity of
the internalized pHrodo.

THP1 Differentiation Into Macrophages
and Stimulation of Interferon Type I
Response

Gene Expression Analysis by nCounter System
(NanoString Technologies)
Total RNA was isolated from FFPE samples. For each
sample, four 10 µm thick FFPE sections were processed
using the Recover All RNA isolation kit (Ambion, Termo
Fisher) following the manufacturer’s protocol. RNA yield

THP1 differentiation to macrophages was performed using
5 ng/ml phorbol 12-myristate 13-acetate (PMA) for 48 h followed
by 24 h of recovery culturing without PMA (25, 26). IFN
I response was induced by high molecular weight poly(I:C)
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protein interaction and a functional connection was done using
the STRING database2 (31).

and fragment length distribution were measured by Qubit
Fluorimeter (Molecular Probes, Termo Fisher) and 2100
Bioanalyzer (Agilent Technologies). The typical yield was 0.8–
1 µg per 10 µm section. As expected, RNAs from archived
FFPE samples were highly degraded (RNA integrity number 2–3);
however, more than 80% of RNA species were over 80 bp allowing
analysis by NanoString technology (hybridization with the 70
nucleotides gene-specific probe). Total RNA (1 µg) was used for
hybridization on a NanoString nCounter platform according to
the manufacturer’s instruction. Samples in which >50% genes
had raw counts below the cutoff of 20 (average of eight negative
controls plus two standard deviations, 95% confidence interval)
were excluded from the analysis.
For gene expression analysis, we used the PanCancer
Immune panel, which contains 730 immunity-related and
cancer genes together with 40 validated housekeeping genes
and a custom CodeSet containing 30 genes designed at
NanoString Technologies. All probe sets were produced in a
single batch. Data were normalized and log2 transformed using
the nSolver 3.0 Analysis Software (NanoString Technologies).
In brief, normalization was performed in two steps: (1)
technical normalization using positive control spikes on each
panel and (2) input amount normalization using the mean
expression of 30 housekeeping genes selected by a geNorm
algorithm on the basis of stability of their expression through
all experimental groups. All transcripts with raw counts
below the threshold 20 [average of eight negative controls
plus two SD (∼95% confidence interval)] were labeled as
undetected. Only genes detected at a level of 30 or more row
counts in at least 50% of our samples were included in the
analysis (N = 493).

Statistical Analysis
Hypergeometric distributions were evaluated using the online
calculator
https://systems.crump.ucla.edu/hypergeometric/
index.php. Other statistical tests were performed using
GraphPad Prism software.

RESULTS
NanoString Profiling Reveals Perturbed
Immune, Microglial and ADRelated Genes in TREM2 R47H AD and
Few Alterations in sAD

Gene set analysis (GSA) (28) was used to calculate significant
enrichment of known transcriptional signatures in gene
expression data from RNA-seq. We used 10,295 gene sets
from the Molecular Signature Database version 4.0 (29). False
discovery rate (FDR) and P-value estimates were computed for
each gene set based on 1,000 separate permutation distributions.
To identify biologically relevant pathways in differentially
expressed (DE) genes from NanoString nCounter data,
we used Ingenuity Pathway Analysis (Ingenuity Systems,
Qiagen) and Metascape1 . Ingenuity Pathway Analysis queries a
proprietary knowledge database and calculates the significance of
genes/pathways enrichment using Fisher’s exact test. Metascape
queries public databases [Reactome, MSigDB, Gene Ontology
(GO), Kyoto Encyclopedia of Genes and Genomes Pathway
(KEGG), and CORUM], using the hypergeometric test to
calculate enrichment. Additionally, Metascape performs an
analysis of protein–protein interactions (data from the BioGrid
database) in which subnetworks with high local network
connectivity are found using the molecular complex detection
algorithm (30). Eight hundred genes on the NanoString panel
were used as a baseline for enrichment calculations. Visualization
of protein–protein association networks that include known

Hippocampi of TREM2 R47H AD patients (N = 8) were
compared with those of sAD (N = 15) and normal aged controls
(N = 17); the latter two groups were chosen to minimize
covariation with age, sex, disease stage, postmortem interval,
and RNA quality (Supplementary Tables 1, 2). Hippocampus
is one of the most affected brain regions in AD, and in a
previous study, we observed the most pronounced changes
in microglial markers in the hippocampi of R47H carriers
(21). We used NanoString nCounter, a mid-throughput nucleic
acid hybridization-based platform suitable for analysis of RNA
from FFPE material. A predesigned PanCancer Immune panel
(770 genes) contained the main human immunity-related
pathways; of those, 156 genes were microglia-specific, i.e.,
expressed at least 10-fold higher in microglia than in other
brain cell populations (32). Of 800 genes on the panel, 551
had detectable expression in FFPE samples, and 493 of these,
including 134 microglia-specific genes (MGs), were included
in the analysis.
At present, the NanoString nCounter is the method of choice
for profiling RNA from FFPE-archived tissues. A recent study
of FFPE AD brains found no major effect of postmortem
interval and RNA degradation on gene expression data (33).
Also, this and other studies reported high concordance of
NanoString expression data in frozen and FFPE material from
the same case (34), and we confirmed this for our samples and
experimental setting. RNA isolated from flash-frozen or FFPE
tissue of the same individual showed high Pearson’s correlation
of gene expression (r2 = 0.84). Additionally, the robustness
of the assay was tested in the “discovery mode” using RNA
from FFPE hippocampi of patients with X-linked parkinsonism
with spasticity (Online Mendelian Inheritance in Man # 300911;
N = 2), a monogenic disorder caused by a variant in the ATP6AP2
gene (21). The mutation alters ATP6AP2 splicing, resulting
in the abnormally high expression of the isoform that skips
exon 4 (e3-e5). We found that e3-e5 was significantly increased
in X-linked parkinsonism with spasticity brains, as previously
shown on RNA prepared from fresh blood cells of carriers
(Supplementary Figure 1). Thus, even in a small group of FFPE

1

2

Gene Set and Pathway Analyses

http://metascape.org
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significance in sAD (Figure 2). Four genes, including TREM2,
were upregulated, and PSEN2 was downregulated. Thus, the
R47H variant has a profound effect on the expression of
AD risk factors.

samples, NanoString nCounter reliably detects gene expression
changes caused by a mutation of predicted effect.
The TREM2 R47H AD group had the largest number of
DE genes (104 vs. 20 in sAD, FDR < 0.1, Figures 1A,B). 75
percent of DE genes in sAD were shared with TREM2 R47H
AD (Figure 1C and Supplementary Table 3). We measured
the relative abundance of microglial cells in the brain tissue by
scoring the expression of 134 MGs (MG signature, Figure 1D).
Both AD groups showed a similar increase in microglia cellularity
compared with controls, suggesting that the observed increase
in immune genes in TREM2 R47 AD is not due to an increased
number of microglia.
We also assessed whether TREM2 R47H affects transcript
levels of TREM2 itself, as well as other known AD genes
and risk factors. Five of 16 genes with measurable expression
were perturbed in TREM2 R47H AD, whereas none reached

Pro-inflammatory Immune Networks and
Pathways Are Activated in TREM2 R47H
AD Brains
The most perturbed pathways in TREM2 R47H AD patients
comprised “WNT/Ca++ Signaling,” “Role of RIG1-like Receptors
in Antiviral Innate Immunity,” “Inflammasome Pathway,” and
“Neuroinflammation Signaling Pathway” (Table 1). Analysis of
the protein–protein interaction network revealed enriched GO
terms corresponding to the regulation of cytokine production
and I-kappaB kinase/NF-kappaB signaling and identified three

FIGURE 1 | Differentially expressed (DE) genes in hippocampi of TREM2 R47H AD and sAD patients. (A–D) Volcano plots displaying DE genes in TREM2 R47H AD
(A) and sAD (B) against a baseline of gene expression in controls. y-Axis corresponds to the log10 (p-value), and the x-axis displays the log2 (FC, fold changes) value.
(C) Venn diagram and list of shared DE genes (FDR < 0.1) between TREM2 R47H AD and sAD. (D) Microglia cell scores were calculated by nSolver (v.3) as an
average log-transformed expression of 134 microglia-specific genes that allow comparison of cell abundance across samples (71). Each unit increase in a cell score
calculated from log2 transformed data corresponds to a doubling of microglia abundance (NS, non-significant; ∗∗∗ p-value < 0.001, ∗∗∗∗ p-value < 0.0001, one-way
ANOVA, and Tukey’s multiple comparison test).
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were not part of the canonical IFN I response signature
(Figure 4B). During IFN I response, multiple downstream
IFN-stimulated genes (ISGs) are upregulated. We, therefore,
queried a database of ISG (INTERFEROME) (36) and found
that DE genes in TREM2 R47H AD were ISG-enriched
(hypergeometric test p-value is 0.03).
Dysregulated IFN I response activates multiple proinflammatory molecules causing cellular stress and cytotoxicity
(37, 38). In TREM2 R47H AD brains, we observed upregulation
of several MHC class I-like NKG2D ligands (MICB, MICA, and
ULBP2, Figure 4C). These molecules are known as “induced
self ” because their expression on the cell surface is induced by
diverse stress agents, such as viruses, heat shock, or oxidative
damage. In the brain, MICB is expressed primarily by microglia
(32), and it is the most significantly upregulated gene in TREM2
R47H AD (Figure 1A). We tested whether MICB may be
upregulated in response to pro-inflammatory stimulation using
a panel of human cell lines that share a myeloid origin with
microglia. Stimulation with a combination of LPS and IFNγ
upregulated MICB expression in all tested cell lines, whereas
stimulation with type 2 cytokines IL-4 or IL-10 had no effect
(Supplementary Figure 2).

FIGURE 2 | Perturbed expression of AD genes/risk factors in TREM2 R47H
AD. AD-associated genes altered (FDR < 0.1) in at least one condition against
a baseline of gene expression in controls are shown. Data are presented as
mean ± SD (∗ adj p-value < 0.05; ∗∗ adj p-value < 0.01); y-axis displays log2
(FC, fold changes) value.

functional modules corresponding to type I interferon response,
ligand-receptor interaction, and a module formed by PSEN2
and mediators of apoptosis (Figure 3). In contrast, sAD
produced a heterogeneous group of overrepresented pathways
driven by the tumor necrosis factor (TNF) receptor superfamily
members (TNFRSF11b and TNFRSF1A) and the NF-κB complex
and its regulators (Table 1). These findings corroborated
a meta-analysis of sAD transcriptomes that identified the
TNF receptor superfamily genes, such as TNFRSF11B and
TNFRSF1A, and components of NFKB signaling, such as
NFKBIA, NFKB1, and RELA, among the top, upregulated
pathways in sAD (35).

TREM2 R47H-Associated Immune
Signatures Are Upregulated in Brain
Transcriptomes of Carriers
We also had flash-frozen unfixed hippocampus tissue suitable for
RNA-Seq analysis from two of the TREM2 R47H carriers. To
assess the top affected pathways at the transcriptome-wide level,
we sequenced the total RNA of these two TREM2 R47H carriers
and three normal age-matched controls. Table 2 shows the top 1%
of differentially regulated gene sets in the brains of TREM2 R47H
carriers (23 of 2,076 sets identified by GSA) (28). Of the 16 most
upregulated sets, 10 belonged to immune process/function, such
as cytokine metabolism, antiviral response/TRAF6-mediated
IRF7 activation, and immune response. The second most
upregulated group consisted of four signatures related to cell
cycle/mitosis. Seven most downregulated sets were related to ion

TREM2 R47H AD Brain Manifests
Activation of Antiviral Response Genes
and “Induced-Self” NKG2D Ligands
The activated antiviral IFN I response and upregulated proinflammatory cytokines were the top immune signatures in
TREM2 R47H brains (Table 1 and Figure 4). We also identified
additional upregulated genes known to act in the antiviral
response (RNF135/Riplet, TLR9, TLR4, and BST2/tetherin) that

TABLE 1 | Top canonical pathways from Ingenuity pathway analysis of DE genes in TREM2 R47H AD and sAD.
Ingenuity canonical pathways

-log(p-value)

zScore

Ratio

Genes

Wnt/Ca + pathway

3.17

2.83

0.67

NFKB2, NFATC3, NFATC4, NFKB1, NFATC2, EP300, CREBBP, NFATC1

Role of RIG1-like receptors in
antiviral innate immunity

2.73

3.00

0.50

MAVS, NFKB2, TRAF2, NFKB1, IRF7, IFIH1, EP300, CREBBP, CASP8,
TRAF6, IKBKE

Inflammasome pathway

2.64

2.65

0.64

TLR4, NFKB2, NFKB1, NOD2, CASP1, CASP8, PYCARD

Neuroinflammation signaling
pathway

2.45

3.54

0.31

TGFB1, NFATC2, TNFRSF1A, TICAM1, IL6R, TLR9, TREM2, CSF1R,
TLR4, IRF7, CREBBP, TRAF6, NFATC4, CCL3, NFKB1, JAK2, EP300,
CASP1, HLA-DOB, APP, MFGE8, NFATC1, PYCARD, NFKB2, NFATC3,
PSEN2, BCL2, TICAM2, CASP3, CD200, CASP8, IKBKE

Induction of apoptosis by HIV1

3.74

0.82

0.25

NFKB2, TNFRSF11B, NFKB1, TNFRSF1A, BCL2, NFKBIA

OX40 Signaling pathway

3.25

1.00

0.21

NFKB2, NFKB1, HLA-DMA, HLA-DRB3, BCL2, NFKBIA

Ceramide signaling

3.14

1.34

0.25

NFKB2, TNFRSF11B, NFKB1, TNFRSF1A, BCL2

PI3K/AKT signaling

3.08

1.64

0.19

NFKB2, NFKB1, INPP5D, ITGB1, BCL2, NFKBIA

TREM2 R47H AD

sAD
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FIGURE 3 | Protein–protein interaction networks and its tightly connected cores (molecular complex detection) formed by differentially expressed genes in TREM2
R47H AD. Protein–protein interaction, molecular complex detection, and Gene Ontology (GO) term enrichment were determined using Metascape
(www.metascape.org). 800 genes on NanoString panel were used as a background for enrichment calculations. Tables with the corresponding GO term enrichment
are shown. Column heading in table: GO, GO ID; Description: Representative GO term; Log10(P), p-value for enrichment.

disorder. In contrast, DE genes in TREM2 R47H AD were
not MG-enriched (30 vs. 27% of expected distribution, hypergeometric test, p = 0.21), suggesting that multiple cell types
have contributed to the activation of an immune response
in this group. PLOSL and TREM2 R47H AD shared only
six DE genes, less than nine expected by chance, and no
common pathways (Figures 5B,C). Top enriched pathways
in PLOSL were “myeloid cell activation involved in immune
response,” “bone development,” and “Fc-gamma Receptormediated Phagocytosis.” We also compared fold changes of
expression of all MG expressed in PLOSL and AD brains.
PLOSL showed the highest magnitude of MG perturbation,
followed by TREM2 R47H AD (Figure 5D). All 19 DE
MGs in PLOSL formed a tight network orchestrated by the
IRF8 transcription factor. The network was enriched with
pro-inflammatory (HLA-DRA, IL18, TNFAIP3, and ITGAX)
and immune signaling molecules (SYK, JAK2, INPP5D, and
PTPRC), endo-phagocytosis mediators (C3, MSR1), and cell
adhesion/motility receptors (CSF3R, ITGAX, OLR1, CD84, and
SELPLG, Figure 5E).

and amino acid transport, endocytosis, glutamine metabolism,
and synaptic transmission (Table 2).
To distinguish whether the upregulation of immune genes was
a characteristic of AD pathology (effect of the disease) or due
to abnormal function of the TREM2 immune receptor (effect
of mutation), we performed GSA analysis on sAD data from
the Blalock study [GDS810 (39)]. This dataset has been used
in several meta-analyses of differential gene expression in AD
(40–43). The study compared hippocampi of the non-demented
control group (N = 9) with three progressive stages of AD:
“incipient” (N = 7), “moderate” (N = 8), and “severe” (N = 7). The
TREM2 R47H and sAD groups shared several downregulated sets
(Table 2), and their enrichment scores increased with disease
progression. Notably, immune sets upregulated in the TREM2
R47H group were not enriched in sAD.

Bi-Allelic Loss-of-Function Mutations in
TREM2 or TYROBP Cause Gross
Perturbation of Microglial Networks in
Brains of PLOSL Patients
PLOSL patients with bi-allelic mutations inactivating either
subunit of the TREM2-TYROBP receptor develop an identical
disease phenotype (4). This prompted us to compare changes in
microglial and immune gene networks caused by the receptor
complex loss with the effect of the TREM2 R47H variant.
We analyzed samples from four PLOSL patients with loss-offunction mutations in TREM2 (N = 2) (4, 22) or TYROBP
(N = 2) (23) by NanoString nCounter. DE genes in PLOSL
(Figure 5A and Supplementary Table 4) were enriched for
MGs (40.4 vs. 27% of expected distribution, hyper-geometric
test, p = 0.027) consistent with the microglial origin of this

Frontiers in Immunology | www.frontiersin.org

TREM2 R47H Restores Defective
Phagocytosis of Aggregated Amyloid
Beta-Peptide in THP1 TREM2 Knockout
Cells
THP1 is a human monocytic cell line used to study monocyte–
macrophage differentiation, signaling, innate immune, and
antiviral responses (44). It constitutively expresses the
TREM2-TYROBP receptor and responds to known TREM2
stimulants, such as IL-4, similar to primary macrophages
(45). Using CRISPR/Cas9 genome editing, we generated
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TABLE 2 | Top gene sets in TREM2 R47H brains are enriched by immunity-related GO terms.
Gene set

GO term

GSA RNA-seq
this study
TREM2 R47H

GSA Blalock et al. 2004 (39)

AD
severe

AD
moderate

AD
incipient

GSA score
Upregulated
MODULE_424

Regulation of immune response
(GO:0050776)

1.41

0.16

0.08

−0.03

Spindle and kinetochore

Mitotic nuclear division
(GO:0007067)

1.28

−0.37

−0.49

−0.69

BIOCARTA_CYTOKINE_PATHWAY

Regulation of cytokine production
(GO:0001817); positive regulation
of JAK-STAT cascade
(GO:0046427)

1.18

−0.05

0.18

−0.15

CYTOKINE_BIOSYNTHETIC_PROCESS

Regulation of cytokine biosynthetic
process (GO:0042035)

1.15

0.01

0.08

0.00

CYTOKINE_METABOLIC_PROCESS

Regulation of cytokine biosynthetic
process (GO:0042035)

1.15

0.01

0.08

0.00

SU_THYMUS

Immune system process
(GO:0002376)

1.13

0.19

−0.21

−0.06

FINETTI_BREAST_CANCER_KINOME_RED

Mitotic cell cycle process
(GO:1903047)

1.13

−0.04

−0.20

−0.54

REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION

Innate immune response
(GO:0045087)

1.09

0.66

0.03

0.12

REGULATION_OF_CYTOKINE_SECRETION

Regulation of cytokine secretion
(GO:0050707)

1.09

0.10

0.05

−0.01

REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS

Regulation of cytokine biosynthetic
process (GO:0042035)

1.08

−0.04

0.06

−0.06

YAMASHITA_LIVER_CANCER_WITH_EPCAM_DN

Steroid metabolic process
(GO:0008202)

1.08

−0.06

0.00

−0.03

MODULE_478

Regulation of immune response
(GO:0050776)

1.03

−0.12

−0.08

−0.26

CROMER_TUMORIGENESIS_UP

Extracellular matrix organization
(GO:0030198)

1.03

0.01

−0.05

−0.06

MODULE_315

Mitotic cell cycle process
(GO:1903047)

1.02

−0.57

−0.46

−0.60

KARAKAS_TGFB1_SIGNALING

Spindle checkpoint (GO:0031577)

1.01

0.09

−0.02

−0.10

CHEN_ETV5_TARGETS_SERTOLI

Immune system process
(GO:0002376)

1.00

0.14

−0.21

0.13

Downregulated
L_AMINO_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY

Amino acid transport (GO:0006865)

−1.35

−0.75

−0.21

−0.20

Oxidative phosphorylation (COX and ATPases)

Hydrogen ion transmembrane
transport (GO:1902600)

−1.19

−1.70

−1.57

−0.60

MODULE_307

Hydrogen ion transmembrane
transport (GO:1902600)

−1.19

−1.72

−1.49

−0.59

BIOCARTA_NDKDYNAMIN_PATHWAY

Endocytosis (GO:0006897),
synaptic transmission
(GO:0007268)

−1.05

−1.05

−0.79

−0.23

BIOCARTA_CACAM_PATHWAY

Protein phosphorylation
(GO:0006468); synaptic
transmission (GO:0007268)

−1.05

−0.83

−0.88

−0.60

LEIN_LOCALIZED_TO_DISTAL_AND_PROXIMAL_ DENDRITES

Activation of phospholipase C
activity (GO:0007202); synaptic
transmission (GO:0007268)

−1.04

−0.72

−0.49

−0.25

GLUTAMINE_FAMILY_AMINO_ACID_METABOLIC_PROCESS

Glutamine family amino acid
metabolic process (GO:0009064)

−1.01

−0.37

−0.28

−0.16

Shown are the top 1% of sets up-or downregulated in carriers of TREM2 R47H, GSA scores ≥ 1 or ≤ -1 (GSA of RNA-seq data, this study). Enrichment of the same
gene sets in sporadic AD was assessed separately by performing GSA of the publicly available dataset of the three sAD cohorts (GSA Blalock et al., 2004) (39).
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FIGURE 4 | TREM2 R47H AD features upregulated interferon type I response and MHC class I-like NKG2D ligands. (A) Role of RIG1-like receptors in antiviral innate
immunity, Ingenuity Pathway Analysis-generated diagram shows perturbed gene expression in TREM2 R47H AD brains. Red denotes upregulated genes; gray, not
changed compared to control brains; white, not assessed. Perturbed expression (FDR < 0.1) of IFN I type response/antiviral genes (B) and MHC class I-like NKG2D
ligands. (C) Data are presented as mean ± SD (∗ adj p-value < 0.05; ∗∗ adj p-value < 0.01); y-axis displays log2 (FC, fold changes) value.

TREM2 KOs in THP1 (Supplementary Figure 3) and created
doxycycline-inducible derivatives that express CV or R47H
TREM2 on the KO background. To study the effect of TREM2
on the phagocytic uptake of Aβ, we treated unmodified
and TREM2 KO THP1 monocytes with pHrodo-labeled,
in vitro aggregated Aβ substrate. Consistent with previous

Frontiers in Immunology | www.frontiersin.org

findings in primary mouse macrophages and microglia
(46), TREM2 ablation significantly reduced the capacity of
human THP1 monocytes to engulf Aβ oligomers (Figure 6).
Interestingly, both CV and R47H TREM2 overexpressed
on the KO background were capable of restoring the Aβ
phagocytic uptake.
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FIGURE 5 | Differentially expressed (DE) and microglia-specific genes in PLOSL. (A) Volcano plots displaying DE genes in PLOSL against a baseline of gene
expression in controls. (B) Venn diagram and list of shared DE genes (FDR < 0.1) between TREM2 R47H AD and PLOSL. (C) Enriched ontology clusters in DE
TREM2 R47H AD and PLOSL. Metascape cluster analysis of GO term enrichment among DE genes (FDR < 0.1) between TREM2 R47H AD and PLOSL. Eight
hundred genes on the NanoString panel were used as a background for enrichment calculations. GO ID, Description: Representative GO term; Log10(P) – p-value for
enrichment. (D) Microglia-specific genes (MG) expression is highly perturbed in PLOSL as compared with AD groups. Distribution of fold changes in MG (N = 134);
X-axis displays log2 of fold changes between gene expression in cases vs. controls (∗ p-value < 0.05; ∗∗∗∗ p-value < 0.0001, one-way ANOVA, Tukey’s multiple
comparison test); (E) Protein–protein association network formed by differentially expressed MG in PLOSL, as visualized by STRING database (http:/string-db.org).
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splice-site mutations (22, 51), and the missense variants D134G,
K186N (4), Y38C, T66M, and V126G (5, 52, 53), have a recessive
mode of inheritance. In contrast, AD-associated R47H has a
dominant mode of inheritance. Whereas pathogenic missense
PLOSL variants affect protein folding and stability, decreasing
TREM2 surface localization, R47H, and other AD-associated
mutations alter the ligand-binding interface of TREM2 (54, 55).
Analysis of TREM2 R47H function in human and mouse reporter
cells showed impaired recognition of certain anionic lipid ligands
(20, 56). These findings are interpreted as a weakened function
not compensated by the normal allele (haploinsufficiency).
Assuming this scenario, heterozygous carriers of known lossof-function TREM2 variants in PLOSL families would also
have increased AD susceptibility. To date, pedigrees with nine
distinct TREM2-inactivating variants have been described across
the world (57), and a study of AD burden in heterozygous
mutation carriers in these PLOSL families would be required to
test this hypothesis. Of several homozygous R47H individuals
reported in Iceland, none manifested a PLOSL-like early-onset
form of dementia, indicating that the variant protein has
retained essential function (2). Given all known limitations of
overexpression studies, our results indicate that TREM2 R47H
does not act as a loss-of-function mutant in the context of Aβ
phagocytosis (Figure 6).
We observed the upregulation of immune and antiviral
defense networks in the brain of heterozygous TREM2
R47H carriers who developed AD. It was exemplified
by the upregulation of pro-inflammatory cytokines and
activation of IFN I response, an important line of defense
against viruses. This pathway is activated upon sensing
viral nucleic acids inside the cell, triggering a cascade
of immune responses that restrict viral propagation and
eliminate infected cells. In the absence of viral infection,
unchecked IFN I response is harmful, being a cause of
Aicardi–Goutières syndrome (AGS), a group of monogenic
interferonopathies that affect the CNS (58). A common RNA
expression phenotype, an “interferon signature,” features
upregulation of IFN I genes in AGS patients. There is no
consensus as to the precise set of genes that constitute
the signature (59), so the subsets may vary considerably
between cases with different mutated genes that cause AGS
and even between patients with the same mutation (60).
Of note, some canonical IFN I response genes, such as STAT1,
STAT2, ISG15, IFIT1, and IFIT2, were not perturbed in
TREM2 R47H AD brains.
The IFN I response signature in the microglia is also
a characteristic of brain aging in humans and mice (61).
Pharmacologic blockade of IFN I signaling ameliorated agerelated cognitive decline in mice. At present, it remains to
be established which aging-associated processes may drive
activation of the IFN I response in the brain. Under certain
circumstances, the antiviral response may be triggered by
reactivation of silenced endoretroviruses (ERVs) or other
transposable elements abundant in the human genome that
mimic double-strand RNA (dsRNA) produced during viral
infection. For instance, DNA methyltransferase inhibition results
in the demethylation of silenced ERV, and their expression

FIGURE 6 | Phagocytosis of aggregated pHrodo-labeled amyloid
beta-peptide. THP-1, unmodified cells; THP-Cas9, THP1 stably expressing
Cas9 nuclease; KO, TREM2 knockout; KO + CV, KO + R47H, KO expressing
common variant (CV) or R47H TREM2, respectively. All cells were treated with
doxycycline, then incubated with pHrodo-labeled Aβ. Data are shown as mean
of biological triplicates ± SD (NS, non-significant; ∗∗ p < 0.01; ∗∗∗ p < 0.001;
and ∗∗∗∗ p < 0.0001, one-way ANOVA, Tukey’s multiple comparison).

TREM2 Has a Stimulatory Role in the
Antiviral Interferon Type I Response in
Myeloid Cells
To investigate the involvement of TREM2 in the IFN I response,
THP1 derivatives were differentiated in vitro to macrophages
with PMA (25, 26). IFN I response was induced by the high
molecular weight RNA-mimetic poly(I:C) in a formulation that
specifically activates the RIG-I/MDA5 (IFIH1) signaling pathway
(47, 48). After 24 h of stimulation, the response was evident from
the upregulation of the IFNB transcript (Figure 7A). Absence
of TREM2 caused a notable decrease of IFNB stimulation in
response to poly(I:C) that was restored by doxycycline-induced
expression of ectopic CV or R47H TREM2 in the KO cells
(Figure 7B). When normalized to the level of TREM2 expression,
R47H had a higher stimulatory effect on IFNB than CV TREM2
(Figure 7C). When derivatives were co-treated with IFNβ and
poly(I:C), a combination is known to potentiate the response,
R47H TREM2 had a superior effect on the IFNB level, as
well as on key IFN type I response genes, such as IRF7 and
IFIH1 (Figure 8). Stimulation of the IFN I response did not
upregulate the NKG2D ligand MICB in unmodified THP1 cells
nor TREM2 KO cells, unlike upon pro-inflammatory stimulation
with LPS + IFNγ (Supplementary Figure 2). Overexpression
of either CV- or R47H-TREM2 in unstimulated KO cells
modestly increased MICB expression, and the effect was the
most pronounced in KO cells overexpressing R47H after IFN
I stimulation. In aggregate, our data indicate a previously
unrecognized role of TREM2 as a positive regulator of IFN I
response in myeloid cells expressing this receptor.

DISCUSSION
Pathogenic TREM2 variants of different effects are found in
several neurodegenerative diseases. In PLOSL, mutations that
inactivate TREM2, including premature stop codons (49, 50),
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FIGURE 7 | TREM2 stimulates IFN I response in THP1 cells. (A) Absence of TREM2 inhibited IFN I response in THP1 TREM2 KO. IFNB expression in non-stimulated
cells and after 24 h with poly(I:C) complexes was measured by qRT-PCR. THP1-Cas9, THP1 stably expressing Cas9 nuclease; KO1, KO2 are two independent
TREM2 KO clones. IFNB expression was normalized to the level in unstimulated THP1-Cas9. FC – fold changes. (B) Overexpression of TREM2, but not GFP,
restored the IFN I response. Assays were performed in biological triplicates and repeated at least two times; (A,B) show representative experiments. KO – TREM2
KO1 cells; KO + GFP – TREM2 KO1 expressing GFP; KO + CV – TREM2 KO1 expressing common variant (CV) TREM2; KO + R47H – TREM2 KO1 expressing
R47H TREM2. All cells were treated with doxycycline. TREM2 and IFNB expression was normalized to their levels in unstimulated KO. (C) Expression of R47H
TREM2 induced a higher level of IFNB as compared with CV TREM2. Ratio of IFNB to TREM2 expression was calculated for TREM2 KO1 THP1 expressing either
CV TREM2 or R47H TREM2 after 24-h poly(I:C) treatment from eight independent biological replicates performed on different days. Data are presented as
mean ± SD. Significance in (A,B) was calculated using two-way ANOVA, Tukey’s multiple comparison test; significance in (C) was calculated using an unpaired
two-tailed t-test (NS, non-significant; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001).

triggers a suicidal IFN I response (62, 63). In aging, transposable
elements undergo profound epigenetic alterations, and their
reactivation is observed in the context of organismal and cellular

Frontiers in Immunology | www.frontiersin.org

senescence in humans and other species (64). Inducing ERV
activation in the mouse brain causes significant hippocampusrelated memory impairment accompanied by robust activation of
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FIGURE 8 | Effect of TREM2 on key interferon (IFN) response genes and the NKG2D ligand MICB upon stimulation with a combination of poly(I:C) and IFNβ. All cells
were treated with doxycycline. Gene expression in non-stimulated cells and after 24 h stimulation was measured by qRT-PCR. THP1, unmodified cells; KO, TREM2
KO1 line; KO + CV, KO + R47H, TREM2 KO1 expressing common variant (CV) or R47H TREM2, respectively. Gene expression levels were normalized to expression
in unstimulated KO. FC, fold changes. Assays were performed in biological triplicates and repeated two times; a representative experiment is shown. Data are shown
as mean ± SD (NS, non-significant; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001, two-way ANOVA, Tukey’s multiple comparison test). Ratio of IFNB to TREM2
expression was calculated for TREM2 KO1 THP1 expressing either CV TREM2 or R47H TREM2 after 24-h poly(I:C) treatment from biological triplicates; data shown
as mean ± SD (∗∗∗ p < 0.001, unpaired two-tailed t-test).
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carriers, together with demonstrated effects of TREM2 KO
and overexpression in myeloid cells, encourage further
testing of the hypothesis that the variant exacerbates the
neurodegenerative process in AD via chronic activation of the
antiviral immune defense.

antiviral immune response mediated through Irf7; the pathology
is attenuated in mice lacking cytosolic viral RNA sensor protein
MAVS (65).
The absence of TREM2 signaling in macrophages
differentiated from KO-THP1 monocytes substantially blunted
the response to viral dsRNA mimetic poly(I:C), seen as a decrease
of IFNB induction. In the “add-back” experiment, the induction
of recombinant TREM2 restored IFNB production. Notably,
the R47H variant induced greater IFNB increase than CV
protein, indicating a possible gain of function in the context
of IFN I response stimulation. We propose a model in which
TREM2 regulates the intensity of the antiviral IFN I response
in specialized innate immune cells expressing this receptor, such
as microglia and macrophages. The epigenetic reprogramming
that occurs in the aging brain may activate transcription of
silenced ERV or other transposable elements, e.g., through DNA
demethylation or changes in histone modifications of their
chromatin. Transcription from repeat elements positioned in
a sense and anti-sense orientation can generate endogenous
dsRNA, which is recognized as foreign and triggers chronic
activation of the IFN I pathway. Trem2 is upregulated in
the course of the acute response to RNA virus in mouse
macrophages (15), Trem2 and TREM2 levels increase with age
in mouse and human brains (66), and TREM2 is elevated in
the brain of R47H carriers. The proposed stimulatory role of
the TREM2 risk allele in AD pathology is consistent with the
small overlap of perturbed genes we observed in PLOSL and
TREM2 R47H AD brains, as well as with inhibited IFN I response
in THP1 TREM2 KO.
When this manuscript was in preparation, we became aware
of another study that analyzed gene expression in TREM2
R47H brains. Prokop and colleagues studied several brain areas
by immunohistochemistry, followed by NanoString nCounter
analysis of RNA isolated from FFPE sections (33). Notably,
TREM2 R47H AD patients presented with a significant increase
of senescent/dystrophic microglia in the hippocampus. R47H
carriers also had elevated immune and microglial activation
scores in the frontal cortex and, to a lower extent, in the
hippocampus. A different choice of predesigned gene panels in
this study and our work may, in part, explain the difference
in the top observed immune gene signatures. The abundance
of senescent microglia in TREM2 AD cases is an intriguing
observation pointing to a possible role of this immune
receptor in accelerated physiological aging of the microglia.
In this light, our finding of co-occurrence of activated proinflammatory and IFN I pathways with upregulated NKG2D
ligands, such as MICA/MICB and ULBP2, in TREM2 R47H
AD brains may be viewed as part of complex senescence
phenotype (67–69).
We acknowledge the limitations of our study engendered
primarily by the rarity of autopsy samples from
TREM2 R47H AD and PLOSL patients, most of which
are limited to FFPE material. Notwithstanding these
constraints, our findings in brains of R47H TREM2
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